Patent intelligence · US
US 8883211
Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds
Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds
Patent details — US 8883211
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 11, 2014
- Expiration
- Nov 6, 2034
- Applicant
- Serina Therapeutics, Inc.
- Claims
- 18
- CPC classes
- A61K, A61K9/1272
Quick answer
US 8883211 (Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds) is held by Serina Therapeutics, Inc.. Status: granted. Granted Nov 11, 2014. Expires Nov 6, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Serina Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K9/1272
More from Serina Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12383626
Polyoxazoline-drug conjugates with novel pharmacokinetic properties
granted -
US 12383625
Polyoxazoline-drug conjugates with novel pharmacokinetic properties
granted -
US 12233132
Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same
granted -
US 11944618
Subcutaneous delivery of polymer conjugates of therapeutic agents
granted -
US 11925689
Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
granted -
US 11766432
Cleavable conjugates of catechol compounds and water-soluble polymers and methods of treatment using the same
granted -
US 11298350
Subcutaneous delivery of polymer conjugates of therapeutics agents
granted -
US 11224595
Subcutaneous delivery of poly(oxazoline) polymer conjugates
granted
Frequently asked questions
What is US patent 8883211?
US 8883211 (Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds) is held by Serina Therapeutics, Inc.. Status: granted. Granted Nov 11, 2014. Expires Nov 6, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8883211?
Serina Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 8883211 expire?
Our index shows an expiration date of Nov 6, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.